Table 1. Demographic and baseline characteristics of the study population.
| Variable | Overall (n = 17) |
|---|---|
| Age | |
| Mean (SD) | 62.0 (±11.9) |
| Median (Min, Max) | 61.0 (40.0, 79.0) |
| Gender | |
| Female | 6 (35.3%) |
| Male | 11 (64.7%) |
| ECOG status | |
| 1 | 10 (58.8%) |
| 2 | 6 (35.3%) |
| 3 | 1 (5.9%) |
| Comorbid illness | |
| CVA | 1 (5.9%) |
| DM | 1 (5.9%) |
| HTN | 5 (29.4%) |
| IHD | 2 (11.8%) |
| None | 8 (47.1%) |
| HIV status | |
| Positive | 0 (0%) |
| Negative | 7 (41.2%) |
| Unknown | 10 (58.8%) |
| Histological differentiation | |
| Moderately differentiated | 8 (47.1%) |
| Poorly differentiated | 5 (29.4%) |
| Well-differentiated | 4 (23.5%) |
| Pre-treatment clinical tumour size | |
| T1 | 3 (17.6%) |
| T2 | 4 (23.5%) |
| T3 | 5 (29.4%) |
| T4 | 5 (29.4%) |
| Pre-treatment nodal involvement | |
| N0 | 8 (47.1%) |
| N1a | 7 (41.1%) |
| N1b | 1 (5.9%) |
| N1c | 1 (5.9%) |
| Pre-treatment clinical stage | |
| Stage I | 3 (17.6%) |
| Stage II | 3 (17.6%) |
| Stage III | 11 (64.7%) |